HEALTH CARE COST AVOIDANCE DUE TO INSULIN GLARGINE FOR TYPE 2 DIABETIC PATIENTS IN HONG KONG AS COMPARED TO NPH INSULIN

被引：0
|
作者：
Lee, K. K. [1 ]
Wu, D. B. C. [2 ]
机构：
[1] Monash Univ, Selangor, Malaysia
[2] Monash Univ, Kuala Lumpur, Malaysia
来源：
VALUE IN HEALTH | 2013年 / 16卷 / 07期
关键词：
D O I：
10.1016/j.jval.2013.08.735
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A451 / A451
页数：1
相关论文
共 50 条
  • [31] Risk of breast cancer in patients exposed to insulin glargine compared to human NPH insulin.
    Boyle, Peter
    Wu, Chuntao
    Sharma, Kristen
    Lin, Stephen
    Juhaeri, Juhaeri
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [32] Improved glycemic control and reduced nocturnal hypoglycemia in patients with type 2 diabetes with morning administration of insulin glargine compared with NPH insulin
    Fritsche, A
    Schweitzer, MA
    Haring, H
    DIABETES, 2002, 51 : A54 - A54
  • [33] Improved glycaemic control and reduced nocturnal hypoglycaemia in patients with Type 2 diabetes with morning administration of insulin glargine compared with NPH insulin
    Fritsche, A
    Schweitzer, MA
    Häring, H
    DIABETOLOGIA, 2002, 45 : A52 - A52
  • [34] No Increased Risk of Breast Cancer in Patients Exposed to Insulin Glargine Compared with Human NPH Insulin
    Boyle, Peter
    Wu, Chuntao
    Sharma, Kristen
    Lin, Stephen L.
    Juhaeri, Juhaeri
    DIABETES, 2018, 67
  • [35] Treatment duration (persistence) of basal insulin supported oral therapy (BOT) in Type-2 diabetic patients: comparison of insulin glargine with NPH insulin
    Quinzler, Renate
    Ude, Miriam
    Franzmann, Alexandra
    Feldt, Sandra
    Schuessell, Katrin
    Leuner, Kristina
    Mueller, Walter E.
    Dippel, Franz-Werner
    Schulz, Martin
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2012, 50 (01) : 24 - 32
  • [36] Total health care costs in medicaid patients receiving NPH, lente, or insulin glargine
    Orsini, LS
    Huse, DM
    DIABETES, 2005, 54 : A144 - A144
  • [37] Insulin glargine is associated with less hypoglycaemia than NPH insulin in older patients with Type 2 diabetes
    Riddle, M
    Massi-Benedetti, M
    Häring, HU
    Dailey, G
    Murray, F
    Lin, Z
    Rosenstock, J
    DIABETOLOGIA, 2004, 47 : A328 - A328
  • [38] Insulin Glargine (GLAR) and NPH Insulin (NPH) in Real Life in Russia in Patients with Type 2 Diabetes (T2D)
    Shestakova, Marina V.
    Glinkina, Irina V.
    DIABETES, 2009, 58 : A530 - A530
  • [39] Impact of diabetes duration on hypoglycaemia in patients with type 2 diabetes treated with insulin glargine or NPH insulin
    Dailey, G. E.
    Gao, L.
    Aurand, L.
    Garg, S. K.
    DIABETES OBESITY & METABOLISM, 2013, 15 (12): : 1085 - 1092
  • [40] Health economic evaluations comparing insulin glargine with NPH insulin in patients with type 1 diabetes: A systematic review
    Hagenmeyer E.-G.
    Koltermann K.C.
    Dippel F.-W.
    Schädlich P.K.
    Cost Effectiveness and Resource Allocation, 9 (1)
12345